The Latest Breaking News from Novartis

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.

Scotland is to become the first part of the UK to routinely screen newborn babies for a 'devastating' rare medical condition ...

Novartis AG (NYSE:NVS) on Monday released topline data from two Phase 3 trials, NEPTUNUS-1 and NEPTUNUS-2, evaluating ianalumab (VAY736) in adults with active Sjögren’s disease.

U.S. trade partners are reacting to President Donald Trump’s executive order that would introduce new tariffs on many of them in seven days

The first malaria treatment for babies and very young children of 2 months up to 5 years was approved for use by Swiss agency for therapeutic products, Swissmedic, in early July 2025. Until now, babies and very young children have been treated with medicines formulated for older children.

Editor’s Note: The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title.

IN FULL

The newly approved medication is a lower-dose version of a tablet previously approved for other age groups

Several African countries where malaria is widespread are expected to swiftly approve the new medicine following Swissmedic’s decision.